GSK will undertake further development of the protein.
EvoGenix has developed improved versions of a protein from GlaxoSmithKline’s (GSK) pipeline using its protein optimization technology, EvoGene™.
"Our technology has been used to finetune the properties of potentially valuable therapeutics," informs EvoGenix CEO, Merilyn Sleigh, “to give them the best chance of success in treating patients safely and effectively, and of going on to become valuable products in the market place."
GSK will be responsible for all subsequent development of the product, with EvoGenix eligible to earn a number of milestone payments as each product progresses through clinical testing toward the market. EvoGenix will also earn royalty payments on sales of products marketed successfully.